ARQT Arcutis Biotherapeutics

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that , President and CEO, will present a corporate overview during the Stifel 2020 Virtual Healthcare Conference taking place November 16-18, 2020.

Details for the presentation are as follows:

        Stifel 2020 Virtual Healthcare Conference

        Presentation Date: Wednesday, November 18, 2020

        Presentation Time: 12:20 p.m. PST / 3:20 p.m. EST

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at . Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit or follow the company on and .

Investor Contact:

Heather Rowe Armstrong

Vice President, Investor Relations & Corporate Communications



805-418-5006, Ext. 740

EN
11/11/2020

Underlying

ARQTArcutis Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcutis Biotherapeutics

 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Announces Publication of Positive Long-Term Safety and Efficac...

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older WESTLAKE VILLAGE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commer...

16h / 20m 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With ...

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2...

October 30, 2025 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment o...

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% provides rapid clearance of atopic dermatitisZORYVE can be used anywhere on the body for any duration and is not a steroidAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercia...

October 30, 2025 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces...

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results   Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October Company provides initial 2026 full year net product sales guidance of $455–$470 million WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherap...

October 28, 2025 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis to Present at Upcoming Investor Conferences

Arcutis to Present at Upcoming Investor Conferences WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in two upcoming investor conferences. Details for the company’s participation are as follows: Guggenheim’s 2nd Annual Healthcare Innovation Conference, November 10-12, 2025        Fireside Chat Date: Tuesday, November 11, 2025        Fireside Chat Time: 8:30 am ET TD Cowen Immunology & Inflamm...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch